Media inquiries: Contact Micaela Dawson, 617-723-2277 ext. 203 or mdawson@pioneerinstitute.org
BOSTON – As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out the key ethical, methodological and disease-specific questions policy makers should address before deciding whether to contract with the Institute for Clinical and Economic Review (ICER) to conduct cost effectiveness reviews used to make decisions about the purchase of medicines and other medical innovations.
ICER utilizes Quality Adjusted Life Years (QALYs), a controversial evaluation technique that assigns an economic value to the longevity and quality of human life.
“The use of the QALY standard in the United Kingdom resulted in British cancer patients having some of the worst access to new cancer treatments in all of Europe and created a political crisis for British politicians,” said William Smith, author of “Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER).” “U.S. politicians may want to proceed cautiously in adopting QALYs.”
QALY is controversial because of the impact that such a methodology may have upon access to medical innovations for older Americans, the disabled, patients with cancer and patients with rare diseases.
The National Health Service (NHS) in the United Kingdom utilizes QALY metrics. But in the United States, the Affordable Care Act banned the use of QALYs for Medicare programs because of concerns about the impact upon older Americans, the disabled and the terminally ill.
Because of the vulnerability of these patient populations, Pioneer recommends that legislators avoid using ICER reviews until they are fully confident that the reviews will neither have an adverse impact upon these vulnerable populations nor discourage biopharmaceutical innovation for important unmet medical needs.
About the Author
William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He has 25 years of experience in government and in corporate roles, including as vice president of public affairs and policy at Pfizer, and as a consultant to major pharmaceutical, biotechnology and medical device companies. He held senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Massachusetts Governor’s office. He is affiliated as research fellow and managing director with the Center for the Study of Statesmanship at The Catholic University of America (CUA), where he earned his PhD.
About Pioneer
Pioneer Institute is an independent, non-partisan, privately funded research organization that seeks to improve the quality of life in Massachusetts through civic discourse and intellectually rigorous, data-driven public policy solutions based on free market principles, individual liberty and responsibility, and the ideal of effective, limited and accountable government.
Oops! We could not locate your form.
Make a tax-deductible gift below to support our work to protect patients.
Related Posts:
State Report Card on Telehealth Reform: Incremental Progress in 2025 Leaves Many States Unprepared for Rural Health Transformation Funding
Study Rates Every State’s Telehealth Laws for Patient Access and Ease of Providing Services
Study Finds Trump’s Most Favored Nation Drug Proposal Could Still Raise Out-of-Pocket Costs Without PBM Reform
Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients
Pioneer Institute Study Calls for Reforms to Ensure that Pharmacy Benefit Manager Practices Benefit Patients, Healthcare Payers
Pioneer Institute: 340B Hospitals Does Not Necessarily Translate to Charity Care
New Online Tool Tracks MA Hospital Revenue from Commercial Sources
Telehealth Progress Slowed in 2023
Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.
Study: High List Prices and Deep Discounts for Prescription Drugs Hurt Poor and Sick Patients
Study: Massachusetts Should Join 45 States and Allow Prescribers to Dispense Medications
As COVID-19 Emergencies Ease, Some Progress on Telehealth Rules
First-of-Its-Kind Interactive Mapping Tool Reveals Extent of For-Profit Entities Benefitting from the 340B Drug Pricing Program
Survey Finds Spotty Compliance Among Hospitals with Federal Price Transparency Law
Massachusetts Hospitals Pull Back on Charity Care as Revenue from Federal 340B Drug Discount Program Explodes
The Promise and Challenges of Rare Cancer Treatments
Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat
Pioneer Institute Statement on the Commonwealth’s Discontinuance of the COVID-19 Weekly Public Health Report
